Adjuvant nivolumab in Muscle-Invasive Urothelial Carcinoma
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a recent article by Matthew D Galsky on LinkedIn:
“Adjuvant nivolumab in Muscle-Invasive Urothelial Carcinoma (MIUC).
Checkmate 274.
OS DATA. In ITT and PdL1 more than or equal to 1 %.
Curves looks impressive.”
Authors: Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky, Michael Schenker, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat, Se Hoon Park, Mads Agerbaek, Gautam Jha, Frank Stenner, Dingwei Ye, Fabio Giudici, Santanu Dutta, Margarita Askelson, Federico Nasroulah, Joshua Zhang, Lynne Brophy and Dean F Bajorin
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023